China is focusing on the pharmaceutical and biotech sectors for growth, and could overtake the US in predictive medicine, gene editing and stem cell research because of easy access to personal data, faster approval of drugs and fewer barriers to human trials. Shanghai and Beijing have set aside CNY10bn ($$10 billion) for start-ups; Suzhou in Jiangsu Province is developing life science parks; and Shenzhen will match private funding and subsidise patents. Cross-border research and development deals between China and the US have increased since 2012, but the Trump administration’s new Committee for Foreign Investment in the US could undermine this.
China is focusing on the pharmaceutical and biotech sectors for growth, and could overtake the US in predictive medicine, gene editing and stem cell research because of easy access to personal data, faster approval of drugs and fewer barriers to human trials. Shanghai and Beijing have set aside CNY10bn ($1.5bn) for start-ups; Suzhou in Jiangsu Province is developing life science parks; and Shenzhen will match private funding and subsidise patents. Cross-border research and development deals between China and the US have increased since 2012, but the Trump administration’s new Committee for Foreign Investment in the US could undermine this.